Launch of Euroscan tablet for treatment of benign prostatic hyperplasia

 

 

 

Euroscan Tablet, a treatment for benign prostatic hyperplasia, has been released.
Uroscan tablets are 5α reductase inhibitors that cause atrophy of the prostate epithelial tissue, reducing the volume of the prostate by 20-30%.
It is also effective in improving urinary flow and reduces the incidence of acute urinary retention and the possibility of surgery.
It has the advantage of showing a more powerful effect when administered in combination with existing Asa products such as Cardil tablets and Euronal extended-release tablets.

▣ Ingredient content: Finasteride 5mg

▣ Efficacy: Treatment of benign prostatic hyperplasia (degeneration of the enlarged prostate, improvement of urinary flow, improvement of symptoms of benign prostatic hyperplasia, reduction in the incidence of acute urinary retention, reduction of the need for surgery including transurethral resection of the prostate and prostatectomy surgery)

▣ Dosage: Take 1 tablet (5mg) once a day, regardless of meal. Even if symptoms improve when taking the drug, treatment for at least 6 months is required.

▣ Insurance price: 813 won

▣ Insurance code: A17603981

▣ Packaging unit: 30 tablets